» Articles » PMID: 12444543

Activation of Cyclin D1-kinase in Murine Fibroblasts Lacking Both P21(Cip1) and P27(Kip1)

Overview
Journal Oncogene
Date 2002 Nov 22
PMID 12444543
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Deregulation of D-type cyclin-dependent kinases (CDK4 and 6) is widely observed in various human cancers, illustrating their importance in cell cycle control. Like other cyclin-dependent kinases (CDKs), assembly with cyclins is the most critical step for activation of CDK4/6. As previously reported elsewhere, we observed that the level of cyclinD1-CDK4 complex and its associated kinase activity were significantly low in asynchronously proliferating mouse embryo fibroblasts lacking both p21(Cip1) and p27(Kip1) (p21/p27-null MEFs). These evidences imply that p21(Cip1) and p27(Kip1) CDK inhibitors are 'essential activators' of cyclin D-kinases. We, however, discovered here that both the assembly and activation of cyclin D1-CDK4 complex occur when quiescent p21/p27-null MEFs were stimulated to re-enter the cell cycle. This mitogen-induced cyclin D1-kinase activity was blocked by overexpression of p16(INK4a) and resulted in the inhibition of S phase entry in p21/p27-null MEFs. Furthermore, ectopic expression of p34(SEI-1), a mitogen-induced CDK4 binding protein, increased the levels of active cyclinD1-CDK4 complex in asynchronously proliferating p21/p27-null MEFs. Together, our results suggest that there are several independent ways to stimulate the assembly of cyclin D1-CDK4 kinases. Although p21(Cip1) and p27(Kip1) play a role in this process, our results demonstrate that additional mechanisms must occur in G0 to S phase transition.

Citing Articles

Targeting CDK4/6 in breast cancer.

Shanabag A, Armand J, Son E, Yang H Exp Mol Med. 2025; 57(2):312-322.

PMID: 39930131 PMC: 11873051. DOI: 10.1038/s12276-025-01395-3.


Lactic acid promotes nucleus pulposus cell senescence and corresponding intervertebral disc degeneration via interacting with Akt.

Zhang Y, Liu L, Qi Y, Lou J, Chen Y, Liu C Cell Mol Life Sci. 2024; 81(1):24.

PMID: 38212432 PMC: 11071984. DOI: 10.1007/s00018-023-05094-y.


CDK4: a master regulator of the cell cycle and its role in cancer.

Baker S, Poulikakos P, Irie H, Parekh S, Reddy E Genes Cancer. 2022; 13:21-45.

PMID: 36051751 PMC: 9426627. DOI: 10.18632/genesandcancer.221.


Cyclin-dependent kinase inhibitors in malignant hematopoiesis.

Schirripa A, Sexl V, Kollmann K Front Oncol. 2022; 12:916682.

PMID: 36033505 PMC: 9403899. DOI: 10.3389/fonc.2022.916682.


Targeting CDK4 and CDK6 in cancer.

Goel S, Bergholz J, Zhao J Nat Rev Cancer. 2022; 22(6):356-372.

PMID: 35304604 PMC: 9149100. DOI: 10.1038/s41568-022-00456-3.